Discontinuation of joint sales of NEOXY® Tape 73.5 mg transdermal overactive bladder treatment medication
2016-03-17

Hisamitsu Pharmaceutical Co., Inc.

Asahi Kasei Pharma Corp.

secondary

Hisamitsu Pharmaceutical Co., Inc., (Head office: Tosu city, Saga Prefecture, Japan; President & CEO: Hirotaka Nakatomi; hereinafter referred to as Hisamitsu) and Asahi Kasei Pharma Corp. (Head office: Chiyoda-ku, Tokyo, Japan; President: Kazuyoshi Hori; hereinafter referred to as Asahi Kasei) reached agreement to discontinue their joint sales of NEOXY® Tape 73.5 mg, a transdermal overactive bladder treatment medication, on June 26, 2016.

While Hisamitsu and Asahi Kasei have jointly sold NEOXY® Tape 73.5 mg since June 2013, the agreement to discontinue joint sales was reached as a result of discussion between the two companies. Asahi Kasei will discontinue sales within three months from June 26, 2016, when its inventory of NEOXY® Tape 73.5 mg is depleted. After that, Hisamitsu will sell NEOXY® Tape 73.5 mg alone.

Reference:

column-header
Trade name
NEOXY® Tape 73.5 mg
Active pharmaceutical ingredient
Oxybutynin hydrochloride
Indication
Urinary urgency, frequent urination, and urge urinary incontinence caused by overactive bladders
Dose and Administration
Usually apply one sheet (73.5 mg of oxybutynin hydrochloride) once a day on the lower abdomen, lower back, or thigh of an adult and replace every 24 hours.
Packaging
70 sheets (1 sheet/pack × 70),
280 sheets (1 sheet/pack × 280)
NHI drug price
194.80 yen/sheet
Date of approval for manufacturing and marketing
March 25, 2013
Date of initial marketing in Japan
June 27, 2013
Manufactured and distributed by
Hisamitsu Pharmaceutical Co., Inc.
imageCaption
false
bottomSpacing
false
buttonPosition
left
spacer
imageCaption
false
bottomSpacing
false
buttonPosition
left

News

imageCaption
false
bottomSpacing
true
buttonPosition
center